A Study of Experimental Medication BMS-986036 Given to Healthy Participants

Completed · Phase 1

Conditions studied: Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis

In brief

This is a study of experimental medication BMS-986036 given to healthy participants.

Key facts

Study ID

NCT03445208

Run by

Bristol-Myers Squibb

People needed

30

Starts

2018-02-14

Expected to finish

2018-05-02

Last updated by the study team

2020-03-19

Who can join

Age: 21 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy participant, as determined by no clinically significant deviations from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
• BMI of 18 to ≤ 40 kg/m2

You may not qualify if…

• Presence of any factors that would predispose the participant to infection (eg, extensive periodontal disease that warrants surgical or medical treatment, unhealed open wounds)
• Any bone trauma (fracture) or bone surgery (i.e. hardware placement, joint replacement, bone grafting, or amputation) within 3 months of study drug administration
• Known or suspected autoimmune disorder, excluding vitiligo
• Any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
• Any significant acute or chronic medical illness
• Current or recent (within 3 months of study drug administration) gastrointestinal disease
• Any major surgery within 6 weeks of study drug administration
• History of diabetes mellitus
• Other protocol defined inclusion/exclusion criteria could apply

Where it is running

• PRA Health Sciences — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.